The Drug That Failed Its Big Test and Still Got FDA Approval

Mitochondria are the power plants inside your cells. They generate the energy (ATP) your body needs to do basically everything, from pumping your heart to lifting your arms. The inner walls of these power plants are lined with a molecule called cardiolipin, which acts like structural scaffolding. Think of it as the rebar inside a concrete building.

In Barth syndrome, that scaffolding is defective. The cardiolipin doesn't form properly, so the mitochondrial walls buckle. Energy production tanks. Organs that need the most energy (the heart, skeletal muscles) take the biggest hit.

Elamipretide is a tiny peptide that binds directly to cardiolipin and helps stabilize that inner membrane structure. It's like sending in an emergency construction crew to shore up the crumbling rebar. With the membrane stabilized, the mitochondria can get back to making energy and dialing down harmful byproducts called reactive oxygen species.

It's an elegant idea. But elegant ideas still have to prove themselves in clinical trials.

The Trial That Didn't Go According to Plan

Stealth's pivotal study, called TAZPOWER, enrolled Barth syndrome patients and randomized them to receive either elamipretide or placebo for 12 weeks. The two primary endpoints were the six-minute walk test (exactly what it sounds like: how far can you walk in six minutes?) and fatigue scores on a Barth-specific symptom questionnaire.

After 12 weeks, the results were underwhelming. Patients on elamipretide walked an average of 443.1 meters. Patients on placebo walked 443.9 meters. That's right: the placebo group actually walked slightly farther. The difference was not statistically significant on either primary measure.

By any conventional standard, the trial missed. If this were a baseball game, the batter struck out looking.

But the story didn't end there. Patients who continued into the open-label extension (where everyone gets the drug and everyone knows it) started showing improvements in walk distance, fatigue, and some measures of strength over longer follow-up periods. The signal got stronger with time.

The Rocky Road to the FDA's Door

Stealth's journey to approval reads like a screenplay about persistence bordering on stubbornness.

The company was founded in 2006 with a focus on mitochondrial-targeted drugs. In 2014, the Barth Syndrome Foundation pushed Stealth to develop elamipretide specifically for their community, recognizing that the drug's cardiolipin mechanism was a near-perfect match for their disease.

Then came the setbacks. A Phase 3 trial in a different mitochondrial disease (primary mitochondrial myopathy) failed in December 2019, missing its endpoints and shaking investor confidence. Stealth pressed forward with Barth syndrome anyway, filing a new drug application in August 2021, but the FDA issued a Refusal to File letter in October 2021. Translation: "We're not even going to review this. Your data package isn't complete enough." The agency pointed to the negative TAZPOWER results and the lack of controlled data in the extension study.

For most companies, that sequence of events (a failed Phase 3 in one disease, a refused filing in another) would be a death sentence. Stealth went back to the drawing board, gathered additional data on knee extensor muscle strength as a surrogate measure, and resubmitted.

Why the FDA Said Yes This Time

The approval came through the accelerated approval pathway, which lets the FDA greenlight drugs based on a surrogate endpoint that is "reasonably likely to predict clinical benefit." In this case, that surrogate was improvement in knee extensor muscle strength.

This is an important distinction. The FDA isn't saying elamipretide definitively helps patients live longer or feel better based on the existing data. It's saying that stronger muscles in Barth syndrome patients are a reasonable proxy for real-world benefit, and that the unmet need is so severe that waiting for perfect data isn't worth the cost.

The approval covers adult and pediatric patients with Barth syndrome who weigh at least 30 kg (about 66 pounds). The drug is given as a once-daily subcutaneous injection.

There's a catch, though. Accelerated approval comes with strings attached. Stealth must now run a confirmatory trial: a randomized, double-blind, placebo-controlled study to verify that the drug delivers real clinical benefit. If that study fails, the FDA can yank the approval. Think of it as a conditional admission: you're in, but you still need to pass the final exam.

The $150 Million Cherry on Top

As if the approval weren't enough, the FDA also handed Stealth a rare pediatric disease priority review voucher. These vouchers are golden tickets in pharma. They allow the holder (or whoever buys the voucher) to get an expedited FDA review on any future drug application.

Recent transactions have valued these vouchers at roughly $100 million to $158 million, with several 2025 and 2026 deals landing around the $150 million mark. For a small biotech like Stealth, selling that voucher could fund the confirmatory trial and then some. It's like winning a scratch-off lottery ticket on top of your regular paycheck.

The voucher program is set to sunset after September 30, 2029, which means each remaining voucher becomes slightly more scarce, and potentially more valuable, as the deadline approaches.

What This Means for Mitochondrial Medicine

Elamipretide's approval isn't just a win for Barth syndrome families. It's a proof of concept for an entire therapeutic category.

Mitochondrial-targeted drugs have been a graveyard of failed clinical programs. The biology is compelling, but translating that biology into measurable outcomes in small, heterogeneous patient populations has been brutally difficult.

Now there's an approved option. And the rest of the field is watching closely.

Several companies are chasing mitochondrial diseases with different approaches. Khondrion is advancing sonlicromanol toward a Phase 3 trial. Minovia earned FDA Fast Track designation for its cell-based therapy MNV-201 in Pearson syndrome (another rare mitochondrial disorder) in mid-2025. A handful of other programs targeting mitochondrial myopathy are scattered across early and mid-stage development.

Elamipretide's approval could serve as a template: use a surrogate endpoint, lean on the accelerated pathway, and demonstrate enough biological plausibility to cross the finish line in ultra-rare diseases where traditional trial designs are nearly impossible.

The Bigger Picture

This story is ultimately about what happens when a disease is so rare that the normal rules of drug development don't quite work. You can't enroll thousands of patients. You can't always hit clean statistical endpoints. The traditional playbook breaks down.

The FDA's decision to approve elamipretide, despite a failed primary endpoint in its pivotal trial, sends a clear signal: for the smallest, sickest patient populations, the agency is willing to flex. Not lower the bar, exactly, but acknowledge that a different kind of evidence can be sufficient when the alternative is no treatment at all.

For the roughly 250 identified Barth syndrome patients worldwide, that flexibility isn't an abstract regulatory debate. It's the difference between waiting indefinitely and having a real, approved medicine for the first time in their lives.

Stealth BioTherapeutics spent nearly two decades getting here. They watched their lead program fail in one disease, get rejected in another, and finally earn approval on what amounts to a second chance. It's not the cleanest path to market anyone has ever taken. But for patients who had nothing, it might just be enough.

Gilead's Lung Cancer Moonshot Just Crashed Back to Earth

Gilead's Trodelvy missed both primary endpoints in a pivotal first-line lung cancer trial, sending shares tumbling roughly 10%. The failure doesn't just hurt Gilead; it raises tough questions about how far TROP-2 antibody-drug conjugates can reach beyond breast cancer.